Neumora Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
NMRA$0.47-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited, in thousands, except per share amounts)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating expenses: | ||
| Research and development | $52,151 | $45,757 |
| General and administrative | 18,785 | 14,317 |
| Total operating expenses | 70,936 | 60,074 |
| Loss from operations | (70,936) | (60,074) |
| Other income (expense): | ||
| Interest income | 3,074 | 6,365 |
| Other expense, net | (25) | (12) |
| Total other income | 3,049 | 6,353 |
| Net loss before income taxes | (67,887) | (53,721) |
| Provision for income taxes | 105 | — |
| Net loss | (67,992) | (53,721) |
| Other comprehensive loss: | ||
| Unrealized loss on marketable securities | (65) | (72) |
| Comprehensive loss | $(68,057) | $(53,793) |
| Net loss per share, basic and diluted | $(0.42) | $(0.34) |
| Weighted-average shares outstanding, basic and diluted | 161,451 | 157,943 |
The accompanying notes are an integral part of these condensed consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.